NEUP (Neuphoria Therapeutics) Total Liabilities: $5.39 Mil (As of Mar. 2026)


NEUP Neuphoria Therapeutics Inc NEUP
32 GF Score
Price $4.47
! 1 Warning Sign
View Full Analysis

What is Neuphoria Therapeutics Total Liabilities?

Neuphoria Therapeutics NEUP +1.59% 32 Total Liabilities is $5.39 Mil as of Mar. 2026. GuruFocus rates NEUP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Neuphoria Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $5.39 Mil.

Neuphoria Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($14.83 Mil) to Dec. 2025 ($6.90 Mil) and declined from Dec. 2025 ($6.90 Mil) to Mar. 2026 ($5.39 Mil).

Neuphoria Therapeutics's annual Total Liabilities increased from Jun. 2023 ($6.55 Mil) to Jun. 2024 ($10.16 Mil) but then declined from Jun. 2024 ($10.16 Mil) to Jun. 2025 ($9.59 Mil).

Neuphoria Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Total Liabilities Chart

Neuphoria Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.01 5.78 6.55 10.16 9.59

Neuphoria Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.72 9.59 14.83 6.90 5.39
NEUP
32GF Score
Neuphoria Therapeutics Inc NEUP
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuphoria Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Neuphoria Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.221+(0+4.871
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.495+0+0)
=9.59

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=28.59-19.003
=9.59

Neuphoria Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.513+(0+3.481
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.391+0+0)
=5.39

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=34.809-29.424
=5.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.39 Mil mean?
Neuphoria Therapeutics (NEUP) has a Total Liabilities of $5.39 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Neuphoria Therapeutics and its competitors.
Is Neuphoria Therapeutics' Total Liabilities too high?
Neuphoria Therapeutics' current Total Liabilities is $5.39 Mil. Overall, Neuphoria Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Total Liabilities compare to PLRZ and SKYE?
Neuphoria Therapeutics' Total Liabilities of $5.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current Total Liabilities is $5.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Total Liabilities of $5.39 Mil. The current Total Liabilities is $5.39 Mil. Neuphoria Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Total Liabilities is $5.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
32GF Score

Get the complete analysis for NEUP

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.47
Price